BIIB · Q2 2025 Earnings
BullishBiogen
Reported July 7, 2025
30-second summary
Biogen raised FY2025 non-GAAP EPS guidance to $15.50–$16.00 (from $14.50–$15.50) and lifted FY revenue from "mid-single-digit decline" to "approximately flat at constant currency" — a meaningful upgrade. Q2 FY2025 revenue grew 7.3% YoY to $2.65B, driven by the four launch products combining for $252M (+91% YoY), with management flipping its framing from "launches cushion MS decline" to "launches drive growth while MS holds in." The market-infrastructure case for Leqembi (PET testing 5x in 18 months, blood biomarker testing nearly tripled, first AA practice guidelines issued) is now mature enough that Biogen has moved to direct-to-consumer.
Headline numbers
EPS
Q2 FY2025
$5.47
Revenue
Q2 FY2025
$2.65B
+7.3% YoY
Gross margin
Q2 FY2025
77.1%
Free cash flow
Q2 FY2025
$0.13B
Operating margin
Q2 FY2025
28.3%
Key financials
Q2 FY2025| Metric | Q2 FY2025 | YoY |
|---|---|---|
| Revenue | $2.65B | +7.3% |
| EPS | $5.47 | — |
| Gross margin | 77.1% | — |
| Operating margin | 28.3% | — |
| Free cash flow | $0.13B | — |
Guidance
Biogen reaffirmed its full-year FY2025 guidance across EPS, revenue growth, and operating expense targets; no material changes to quantitative outlook.
Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.
Reaffirmed unchanged this quarter: Non-GAAP Diluted EPS ($15.50–$16.00), Total Revenue Growth (Approximately flat vs FY2024 at constant currency), Non-GAAP R&D and SG&A Combined Expense (Approximately $4.0 billion)
Segment KPIs
Q2 FY2025| Segment | Q2 FY2025 | YoY |
|---|---|---|
| Multiple Sclerosis (MS) | $1.107B | -3.7% |
| Rare Disease | $0.543B | +1.7% |
| Biosimilars | $0.182B | -8.3% |
| Other Product Revenue | $0.047B | +169.5% |
| Anti-CD20 Therapeutic Programs Revenue | $0.467B | +5.1% |
| Alzheimer's Collaboration Revenue | $0.055B | +366.7% |
| Contract Manufacturing, Royalty and Other Revenue | $0.245B | +124.4% |
Other KPIs
Q2 FY2025| Segment | Q2 FY2025 |
|---|---|
| LEQEMBI U.S. In-Market Sales | $63 million |
| LEQEMBI Global In-Market Sales | $160 million |
| LEQEMBI U.S. Sequential Growth | 20% |
| SKYCLARYS Global Revenue | $130 million |
| SKYCLARYS U.S. Sequential Growth | 13% |
| ZURZUVAE Revenue | $46 million |
| ZURZUVAE Sequential Growth | 68% |
| Operating Margin | 28.3% |
Management tone
Q4 FY2024 MS-cliff defense → Q1 FY2025 launch portfolio gaining → Q2 FY2025 launches lead, MS resilient, pipeline catalysts ahead
The dominant shift across the last three quarters is from defending the MS cliff to crediting the launch portfolio with offsetting it — and now to framing MS as "more resilient than expected." Management was explicit: "We've seen growth, the growth from our new product launches offsetting our MS decline. MS has also proven to be a little bit more resilient this quarter." Biogen's typical posture has been to frame quarters around how much MS erosion the rest absorbed; here the framing has flipped to growth-led with MS as a smaller-than-feared drag. The EPS raise validates the shift quantitatively.
Leqembi commentary has migrated over three quarters from "build infrastructure" to "infrastructure is maturing" to "the market is ready, so we're going direct to consumer." The anchor quote: "This maturing of the market infrastructure gave us confidence earlier this year to launch new initiatives." Specifics back it — PET testing up 5x in 18 months, blood biomarker testing up 50% in the past six months, ~30% of customers diagnosing MCI/mild-AD for the first time. The patient-facing DTC message ("Leqembi can help them still be like themselves longer") is identity-preservation language, not the clinical-efficacy language of a cautious launch team.
Skyclarys has shifted across the year from a centers-of-excellence story with bounded TAM to a community-driven product. "Approximately 70% of new start forms were written by the community neurologists and PCPs. This reinforces our belief in our ability to reach the remaining patient population in need." The +13% U.S. QoQ growth is the channel pivot showing through in the print — and it implies the prior CoE-only TAM understated the opportunity.
The pipeline narrative gained a new pillar this quarter that was barely present a year ago. "The next 12 to 18 months are marked by multiple key expected scientific milestones and regulatory outcomes, including Leqembi subcutaneous maintenance and high-dose Spinraza." Last year pipeline was framed as incremental; now it is the central forward narrative, with Felzartamab Phase 3 trials all initiated, Salinersen advancing, and Zuranolone progressing.
The "at constant currency" qualifier added to FY2025 revenue guidance is the one defensive tonal note — management is hedging FX while otherwise pressing forward.
Recurring themes management leaned on this quarter:
Risks management surfaced:
Q&A highlights
Phil Nadeau · TD Cowan
Inquiry about AHEAD 345 trial interim analysis plans and design differences compared to Trailblazer LS3 in early Alzheimer's disease
Management clarified that AHEAD 345 consists of two trials: AHEAD 3 (examining amyloid accumulation prevention) and AHEAD 445 (examining cognitive decline prevention in patients with >40 centiloids amyloid). Key differences from competitor include use of amyloid PET screening, CDR global score of zero inclusion criteria, and sensitive biomarker/composite endpoints. Data expected in 2028.
Eric Schmidt · Cantor
Question on Likendi market share dynamics and impact of competitor Cassinla's recent safety label update
Management reported Likendi maintaining ~70% market share despite competitive pressure. Growth from competitor primarily comes from existing Likendi prescribers at same sites. Market expanded ~15% in new patient starts. Noted that competitor faces same health system friction points. Upcoming maintenance and sub-Q options provide additional differentiation. Competitor's label update reflects dosing patterns already in use; MRI burden unchanged.
David Amsallam · Piper Sandler
Question on lupus pipeline including Daprolizumab Phase 3 timing and competitive positioning against oral agents like Lexotictu
Management emphasized tackling lupus heterogeneity with multi-mechanistic approach. Daprolizumab targets CD40 pathway affecting both T and B cells with Phase 3 data showing impact on severe flares and steroid sparing. Lutafilumab targets type one interferon signature with Phase 2 proof of concept. Second Phase 3 expected 2027-28; Lutafilumab SLE data expected late 2025. Referenced MS market where orals represent ~1/3 of market despite being available; emphasized efficacy and mechanism differences matter.
Brian Abrams · RBC Capital Markets
Question on expansion of blood-based biomarkers for patient triage and timeline for replacing PET/CSF diagnostics
Management noted blood-based biomarker testing nearly tripled in past year; Alzheimer's Association issued first practice guidelines. Tests gaining neurologist adoption but primarily used for triage. Majority of physicians still confirming positive/indeterminate tests with CSF/PET. Key opportunity is establishing blood tests as standard for amyloid confirmation. Barriers include need for reimbursement clarity with CMS and education on new guidelines.
Ymir Raffat · Evercore
Question on ESI partnership status and arbitration related to European commercialization allocation disagreements
Management characterized ESI relationship as 'better than it has ever been' with strong executive engagement across committees and close working relationships on development and manufacturing. Acknowledged arbitration filed over European launch approach reflects normal disagreement in partnerships; stated it follows contractual process and hasn't affected overall working relationship. Emphasized 10+ year partnership and continued commitment to Aduhelm investment.
Answers to last quarter's watch list
What to watch into next quarter
Launch portfolio sequential print in Q3 FY2025. A flat or down result vs. the $252M Q2 FY2025 base would suggest Q2's +26% QoQ pulled forward demand. Above $270M would confirm a new run-rate.
Leqembi U.S. QoQ growth post-DTC. Q2 FY2025 was +20% QoQ before DTC effects could meaningfully flow through; if Q3 FY2025 doesn't accelerate from there, the DTC investment is not converting. Watch also for the sub-Q maintenance PDUFA outcome and Leqembi U.S. in-market sales above $75M.
MS YoY decline rate ex-inventory/true-up benefits. Q2 FY2025's -3.7% YoY MS line embeds ~$80M of one-time U.S. favorability. Strip it out and the underlying erosion is steeper — watch whether the Q3 FY2025 print reveals the underlying rate, particularly with Tecfidera generics and Tysabri biosimilars arriving.
Whether the "at constant currency" qualifier on FY2025 revenue guide implies a reported revenue miss. The qualifier was added this quarter; if reported FY2025 revenue prints down low-single-digits, the headline "approximately flat" framing will look stretched.
Skyclarys community channel mix and Q3 FY2025 QoQ growth. Community-channel share holding above 60% of new starts and U.S. growth sustaining double-digit QoQ confirm the pivot is not a one-quarter effect.
Litifilimab SLE topline readout (late 2025). A positive readout extends the "deep immunology capability" narrative into a second franchise; a miss leaves Daprolizumab carrying the lupus thesis alone until 2027–28.
Sources
- Biogen Q2 FY2025 earnings press release (Form 8-K, Exhibit 99.1): https://www.sec.gov/Archives/edgar/data/875045/000087504525000035/exhibit991-q22025pressrele.htm
- Biogen Q2 FY2025 earnings call — prepared remarks and Q&A
Get the next brief, free.
We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.
This is not investment advice.